Tolerability, Safety and Efficacy of the HAC-Coil Deep Transcranial Magnetic Stimulation in Medication Resistance Obsessive Compulsive Disorder (OCD) Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test whether the combination of deep transcranial magnetic stimulation (DTMS) treatment with customary medication for obsessive compulsive disorder (OCD) patients is effective than treatment that include only medication.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Accelerated Rotational Field Deep TMS for Treating OCD

NCT07116785

Obsessive-Compulsive Disorder

RECRUITING NA

Evaluation of the Deep TMS H-Coil in the Treatment of Major Depression- Augmentation of Antidepressant Medication

NCT00460902

Major Depression

COMPLETED PHASE1/PHASE2

Evaluation of the Long Term Efficacy and Durability of the BrainsWay Deep TMS in OCD Subjects

NCT05404360

Obsessive-Compulsive Disorder

UNKNOWN NA

Deep Transcranial Magnetic Stimulation (TMS)- Treatment for Post Traumatic Stress Disorder

NCT00517400

Post Traumatic Stress Disorder

COMPLETED PHASE1/PHASE2

A Safety & Efficacy Study With Deep Transcranial Magnetic Stimulation for the Treatment of Post-Traumatic Stress Disorder (PTSD)

NCT02479906

Post-Traumatic Stress Disorder

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obsessive Compulsive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

healthy volunteeres

this arm will undergo only EEG measurement

Group Type NO_INTERVENTION

No interventions assigned to this group

real - low frequency

this arm will receive DTMS treatment with low frequency

Group Type ACTIVE_COMPARATOR

Deep TMS

Intervention Type DEVICE

deep transcranial magnetic stimulation

real - high frequency

this arm will receive DTMS treatment with high frequency

Group Type ACTIVE_COMPARATOR

Deep TMS

Intervention Type DEVICE

deep transcranial magnetic stimulation

sham - low / high frequency

this arm will receive DTMS sham treatment with low or high frequency

Group Type SHAM_COMPARATOR

Deep TMS

Intervention Type DEVICE

deep transcranial magnetic stimulation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Deep TMS

deep transcranial magnetic stimulation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Outpatients
2. Men and Women 18-65 years of age.
3. Diagnosed as suffering from OCD according to DSM-IV.
4. Patients having OCD of at least moderate severity (YBOCS score of 20 or above).
5. Patients are maintained on an medication at steady dosages for at least 8 weeks before study entry and for the duration of the trail.
6. Negative answers on safety screening questionnaire for transcranial magnetic stimulation.
7. According to the treating physician the patients is compliant with taking medication.
8. Capable and willing to provide informed consent.
9. Able to adhere to treatment schedule.
10. Patients that participate in behavioral therapy, will be in the maintaining stage and not in the active or intensive stage.

Exclusion Criteria

1. Any other Axis I diagnosis as the primary diagnosis.
2. History of epilepsy or seizure (EXCEPT those therapeutically induced by ECT) or history of such in first degree relatives).
3. OCD patients that have only symptoms of hoarders)
4. patients with Suicidal tendencies, or the patients is diagnosed as having a Suicidal tendencies by the treating physician.
5. Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure, or history of significant head trauma with loss of consciousness for greater than or equal to 5 minutes.
6. History of head injury necessitating cranial surgery or prolonged coma.
7. History of any metal in the head including the eyes and ears (outside the mouth).
8. Known history of any metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or implanted medical pumps.
9. History of frequent or severe headaches.
10. History of migraine.
11. History of significant hearing loss.
12. Individuals with a significant neurological disorder or insult including, but not limited to:

Any condition likely to be associated with increased intracranial pressure Space occupying brain lesion History of cerebrovascular accident Transient ischemic attack within two years Cerebral aneurysm Dementia Parkinson's disease Huntington's chorea Multiple sclerosis
13. History of substance abuse including alcoholism within the past 6 months (except nicotine and caffeine).
14. Inadequate communication with the patient.
15. Participation currently in another clinical study or enrolled in another clinical study within 30 days prior to this study.
16. Participants who suffer from an unstable physical, systemic and metabolic disorders such as instabilized blood pressure or acute, unstable cardiac disease.
17. Women who are breast-feeding.
18. Known or suspected pregnancy.
19. Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No